Hepion Pharmaceuticals Stock (NASDAQ: HEPA)

Hepion Pharmaceuticals (NASDAQ:HEPA) Stock, Quote.Headers.trade-ideas

Hepion Pharmaceuticals

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Business,Handshake

Biotech

Equities

News

Health Care

Movers

Trading Ideas

General

HEPA

Hepion Pharmaceuticals announces merger with Pharma Two B Ltd., creating a combined company focused on Parkinson&#39;s disease treatment. The merger values Hepion at $58.5 million, and Pharma Two B plans to list on Nasdaq under &#34;PHTB&#34;.

Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson&#39;s Disease Drug Developer

Stock Market

Eurozone

Commodities

Intraday Update

Markets

MLEC

MTTR

NIVF

VAXX

WRNT

ZION

S&amp;P 500 Rises Over 1%; Zions Bancorp Shares Gain After Q1 Earnings

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Updates on Hepion Pharmaceuticals&#39; ASCEND-NASH Trial, now in wind-down phase. Explore insights into Phase 2b study progression and strategic alternatives.

Why Is Liver-Disease Drug Developer Hepion Pharmaceuticals Stock Trading Lower On Monday?

Hepion Pharmaceuticals, Inc. - Common Stock

Hepion Pharmaceuticals Inc

WHLRD

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

WHLRP

WHLRL

WHLR

Millions of Americans face tougher times managing their bills as inflation bites. According to the U.S. Census Bureau, about 40% of consumers say it&#8217;s getting &#8220;somewhat&#8221; to &#8220;very difficult&#8221; to cover their monthly expenses.&nbsp;
This struggle is set to deepen with the return of student loan payments, which paused for years during the pandemic. Add to that the cost of summer child care and vacations and it's no wonder many are feeling the heat. But there's one payment you can't afford to put on the back burner: your student loans.
Don't Miss:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"> The percentage may shock you</a>.</li>
<li>This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a></li>
</ul>
Financial expert <a href="https://www.benzinga.com/personal-finance/24/08/40304035/suze-orman-says-ignoring-this-will-ruin-your-investment-future-heres-what-you-must-do-now-to-sec">Suze Orman</a>, host of the popular &#8220;Women &amp; Money&#8221; podcast, warns that skipping student loan payments is not an option. "It should be a priority," she said.
Pushing student loans aside with everything else on your plate might be tempting, but ignoring them could land you in hot water. The restart of these payments in fall 2023 has forced many people to figure out how to squeeze them back into already-tight budgets. However, Orman stresses that this is one bill you can't sweep under the rug.
Trending: Founder of Personal Capital and ex-CEO of PayPal<a href="https://www.benzinga.com/money/evergreen-money"> re-engineers traditional banking with this new high-yield account — start saving better today.</a>
Orman offers practical advice for those overwhelmed: &#8220;Make a plan or a budget that works so you can pay [your student loans] each month.&#8221; Her suggestion? Start by trimming the fat from your spending.&nbsp;
&#8220;Give up eating out or other unnecessary expenses so you can start making your payments,&#8221; she advises. Cutting back on indulgences can free up the cash needed to keep up with loan payments and it's a simple step toward regaining control over your finances.
Trending: Elon Musk and Jeff Bezos are bullish on one city that could dethrone New York and become the new financial capital of the US.<a href="https://www.benzinga.com/money/miami-take-new-yorks-place-financial-capital"> Investing in its booming real estate market has never been more accessible.</a>
The silver lining is that the <a href="https://www.benzinga.com/personal-finance/24/09/40879305/the-22-6-trillion-crisis-neither-harris-nor-trump-mentioned-but-its-the-top-concern-for-millions">Biden </a>administration has rolled out a new income-driven repayment (IDR) plan called the Saving on a Valuable Education (SAVE) Plan. This plan could offer significant relief to borrowers, especially those on the lower end of the income scale.
According to the Department of Education, single borrowers earning $32,800 or less and families of four earning $67,500 or less won't need to make any payments at all. Even those earning more will see some savings – at least $1,000 annually compared to older IDR plans.
See Also: <a href="https://www.benzinga.com/money/irs-finalizes-10-year-rule-adv">IRS Finalizes 10-Year Rule For Retirement Withdrawals, Making Things &#8216;Even More Insanely Complicated&#8217;</a>
"With the new guidelines, many people's payments will be cut in half," Orman explained. This makes it much more manageable to stay on top of those monthly payments, reducing the risk of falling behind. For borrowers feeling stretched thin, this adjustment might just be their lifeline.
There's no sugarcoating it – budgeting for loan payments can feel like a juggling act. But as Orman points out, it's a necessity. &#8220;People need to remember not to put off paying your student loans. It's not going away; it should be the first monthly bill you pay. You can't bankrupt your student loan.&#8221;
Read Next:
<ul>
<li>Unlock the hidden potential of commercial real estate —<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a></li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>

Personal Finance

Suze Orman Says Missing This One Crucial Monthly Payment Could Cost You Big – Here's The First Bill You Should Never Ignore

Jefferies analyst Julien Dumoulin-Smith initiates coverage on Portland Gen Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) with a Hold rating and announces Price Target of $48.

Price Target

Initiation

Analyst Ratings

Jefferies Initiates Coverage On Portland Gen Electric with Hold Rating, Announces Price Target of $48

Jefferies analyst Paul Zimbardo initiates coverage on Dominion Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>) with a Hold rating and announces Price Target of $58.

Jefferies Initiates Coverage On Dominion Energy with Hold Rating, Announces Price Target of $58

Jefferies analyst Julien Dumoulin-Smith initiates coverage on American Electric Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) with a Hold rating and announces Price Target of $107.

Jefferies Initiates Coverage On American Electric Power with Hold Rating, Announces Price Target of $107

Jefferies analyst Julien Dumoulin-Smith initiates coverage on Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>) with a Hold rating and announces Price Target of $94.

Jefferies Initiates Coverage On Southern with Hold Rating, Announces Price Target of $94

Jefferies analyst Julien Dumoulin-Smith initiates coverage on Idacorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDA#NYSE">IDA</a>) with a Hold rating and announces Price Target of $110.

Jefferies Initiates Coverage On Idacorp with Hold Rating, Announces Price Target of $110

Jefferies analyst Julien Dumoulin-Smith initiates coverage on WEC Energy Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>) with a Hold rating and announces Price Target of $102.

Jefferies Initiates Coverage On WEC Energy Group with Hold Rating, Announces Price Target of $102

The head-to-head matchup between former President Donald Trump and Vice President Kamala Harris could come down to how several swing states fall in the<a href="https://www.benzinga.com/topic/2024-election"> 2024 presidential election.</a>
A new poll shows which candidate is making up ground in the key seven states.
What Happened: Harris has been trending up <a href="https://www.benzinga.com/general/politics/24/09/40910999/trump-in-trouble-vice-president-harris-has-record-6-point-lead-in-2024-election-poll-after-debat">in 2024 election polls</a> of nationally registered voters, posting her largest lead in the weekly Morning Consult poll this week in the head-to-head matchup.
A new poll of <a href="https://www.benzinga.com/topic/swing-states">swing state</a> voters, which covers seven key battleground states, could show a different picture.
Here are the results from the September Emerson College swing state <a href="https://emersoncollegepolling.com/september-2024-swing-state-polls-trump-and-harris-locked-in-tight-presidential-race/">polls </a>with the results from August in parentheses:
<ul>
<li>Arizona: Trump 49% (50%), Harris 48% (47%)</li>
<li>Georgia: Trump 50% (48%), Harris 47% (49%)</li>
<li>Michigan: Harris 49% (50%), Trump 47% (47%)</li>
<li>Nevada: Trump 48% (48%), Harris 48% (49%)</li>
<li>North Carolina: Harris 49% (48%), Trump 48% (49%)</li>
<li>Pennsylvania: Trump 48% (48%), Harris 47% (48%)</li>
<li>Wisconsin: Trump 49% (49%), Harris 48% (48%)</li>
</ul>
The results show that Trump leads Harris in four of the seven states and is tied with the vice president in one state. Harris leads Trump in two states. Each candidate led three states in the August poll.
Trump gained support in one state and lost support in two states, with four states remaining the same from August. Harris gained support in two states and lost support in four states.
"There has been marginal movement in the presidential election since the late August Emerson swing state polls before the presidential debate," Emerson College Polling executive director Spencer Kimball said. 
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent091924">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: The seven swing states in question together represent 93 electoral votes in the 2024 election. Six of the seven states above were won by Biden in the 2020 election with Trump winning North Carolina. Several of the states were flipped from Trump's win in the 2016 election.
A Marist poll recently found how swing state voters in Michigan, Pennsylvania and Wisconsin would vote in the 2024 election if it were held today. The race for Pennsylvania and Wisconsin was close with Trump and Harris tied in Pennsylvania and Harris leading by one point in Wisconsin.
In the state of Michigan, Harris had a five-point lead over Trump.
The three states together represent 44 electoral votes and could prove important in the 2024 election. Trump was the first Republican presidential candidate to sweep the three states since Ronald Reagan in 1984, <a href="https://nypost.com/2024/09/19/us-news/trump-harris-neck-and-neck-among-likely-voters-in-pennsylvania-and-wisconsin-veep-up-5-in-michigan-polls/">according </a>to the New York Post. Biden won all three of the states in the 2020 election.
All seven swing states see voters pick the economy as the top issue ahead of the election. Immigration, threats to democracy and housing affordability are also top voter issues in swing states.
With less than two months until the 2024 election, the race between Harris and Trump remains close and swing states continue to be one of the most monitored polling items given their importance.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent091924">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Photo: Shutterstock

Politics

Harris In Trouble? New Swing State Poll Shows Trump Gains Ground In Key Battleground Areas For 2024 Election

Jefferies analyst Paul Zimbardo initiates coverage on Xcel Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XEL#NASDAQ">XEL</a>) with a Hold rating and announces Price Target of $70.

Jefferies Initiates Coverage On Xcel Energy with Hold Rating, Announces Price Target of $70

Jefferies analyst Julien Dumoulin-Smith initiates coverage on Alliant Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNT#NASDAQ">LNT</a>) with a Hold rating and announces Price Target of $67.

Jefferies Initiates Coverage On Alliant Energy with Hold Rating, Announces Price Target of $67

Jefferies analyst Julien Dumoulin-Smith initiates coverage on OGE Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGE#NYSE">OGE</a>) with a Buy rating and announces Price Target of $46.

Jefferies Initiates Coverage On OGE Energy with Buy Rating, Announces Price Target of $46

Jefferies analyst Julien Dumoulin-Smith initiates coverage on Ameren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>) with a Buy rating and announces Price Target of $97.

Jefferies Initiates Coverage On Ameren with Buy Rating, Announces Price Target of $97

Jefferies analyst Julien Dumoulin-Smith initiates coverage on Evergy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVRG#NASDAQ">EVRG</a>) with a Buy rating and announces Price Target of $70.

EVRG

Jefferies Initiates Coverage On Evergy with Buy Rating, Announces Price Target of $70

Jefferies analyst Julien Dumoulin-Smith initiates coverage on Pinnacle West Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNW#NYSE">PNW</a>) with a Buy rating and announces Price Target of $104.

Jefferies Initiates Coverage On Pinnacle West Capital with Buy Rating, Announces Price Target of $104

Jefferies analyst Julien Dumoulin-Smith initiates coverage on Exelon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>) with a Buy rating and announces Price Target of $46.

Jefferies Initiates Coverage On Exelon with Buy Rating, Announces Price Target of $46

Jefferies analyst Paul Zimbardo initiates coverage on PPL (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPL#NYSE">PPL</a>) with a Buy rating and announces Price Target of $38.

Jefferies Initiates Coverage On PPL with Buy Rating, Announces Price Target of $38

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Hepion Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/hepa-stock-quote/">HEPA</a>) just reported results for the fourth quarter of 2023.<ul><li>Hepion Pharmaceuticals reported earnings per share of -$2.42. This was above the analyst estimate for EPS of -$2.63.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/hepa-stock-earnings-hepion-pharmaceuticals-for-q4-of-2023/">HEPA Stock Earnings: Hepion Pharmaceuticals Beats EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

HEPA Stock Earnings: Hepion Pharmaceuticals Beats EPS for Q4 2023

Hepion ends Phase 2 study for NASH drug due to cash restraints

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start off the trading week with a look at the biggest pre-market stock movers for Monday morning!



Moving stocks this morning are earnings, investments, a delisting and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Moolec Science (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlec-stock-quote/">MLEC</a>) stock is rocketing more than 67% on approval for its <a href="https://www.nasdaq.com/press-release/moolec-becomes-first-molecular-farming-company-to-achieve-usda-approval-for-plant">plant-groan animal proteins</a>.</li>



<li>OLB Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/olb-stock-quote/">OLB</a>) shares are soaring over 46% with heavy pre-market trading.</li>



<li>Complete Solaria (NASDAQ:<a href="https://investorplace.com/stock-quotes/cslr-stock-quote/">CSLR</a>) stock is surging more than 42% <a href="https://www.nasdaq.com/press-release/retail-stock-sector-and-chairman-t.j.-rodgers-invest-in-complete-solaria-2024-04-21">on investment news</a>.</li>



<li>SuperCom (NASDAQ:<a href="https://investorplace.com/stock-quotes/spcb-stock-quote/">SPCB</a>) shares are gaining over 33% ahead of its <a href="https://www.nasdaq.com/press-release/supercom-to-report-fourth-quarter-and-full-year-2023-financial-results-on-april-22">Q4 2023 earnings report</a> this morning.</li>



<li>Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) stock is rising more than 18% on Monday morning.</li>



<li>Galera Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/grtx-stock-quote/">GRTX</a>) shares are increasing over 17% without any clear news this morning.</li>



<li>Palisade Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/pali-stock-quote/">PALI</a>) stock is climbing more than 16% despite a lack of news today.</li>



<li>Global Gas (NASDAQ:<a href="https://investorplace.com/stock-quotes/hgas-stock-quote/">HGAS</a>) shares are heading over 14% higher on Monday.</li>



<li>Volato (NYSEMKT:<a href="https://investorplace.com/stock-quotes/soar-stock-quote/">SOAR</a>) stock is jumping more than 13% on Monday morning.</li>



<li>Portage Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/prtg-stock-quote/">PRTG</a>) shares are up over 13% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Vaxxinity (NASDAQ:<a href="https://investorplace.com/stock-quotes/vaxx-stock-quote/">VAXX</a>) stock is crashing more than 55% on the company&rsquo;s <a href="https://finance.yahoo.com/news/vaxxinity-announces-intention-voluntarily-delist-202700884.html">plans to delist its shares</a>.</li>



<li>EzFill (NASDAQ:<a href="https://investorplace.com/stock-quotes/ezfl-stock-quote/">EZFL</a>) shares are plummeting close to 37% this morning.</li>



<li>Hepion Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/hepa-stock-quote/">HEPA</a>) stock is diving over 29% on plans to <a href="https://www.nasdaq.com/press-release/hepion-pharmaceuticals-initiates-wind-down-activities-in-phase-2b-ascend-nash-trial">wind down a clinical trial</a>.</li>



<li>iLearningEngines (NASDAQ:<a href="https://investorplace.com/stock-quotes/aile-stock-quote/">AILE</a>) shares are tumbling more than 21% after <a href="https://finance.yahoo.com/news/ilearningengines-inc-becomes-publicly-traded-200500132.html">going public last week</a>.</li>



<li>Redwoods Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/rwod-stock-quote/">RWOD</a>) stock is taking an over 15% beating <a href="https://investorplace.com/2024/04/why-is-redwoods-acquisition-rwod-stock-up-72-today/">after a recent rally</a>.</li>



<li>Biophytis (NASDAQ:<a href="https://investorplace.com/stock-quotes/bpts-stock-quote/">BPTS</a>) shares are sliding more than 15% ahead of <a href="https://www.nasdaq.com/press-release/biophytis-announces-ratio-change-under-its-american-depositary-receipt-adr-program-0">a ratio change tomorrow</a>.</li>



<li>Adlai Nortye (NASDAQ:<a href="https://investorplace.com/stock-quotes/anl-stock-quote/">ANL</a>) stock is dropping nearly 15% today.</li>



<li>BioSig Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/bsgm-stock-quote/">BSGM</a>) shares are falling over 13% this morning.</li>



<li>Sunshine Biopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/sbfm-stock-quote/">SBFM</a>) stock is decreasing more than 12% today.</li>



<li>Indonesia Energy (NYSEMKT:<a href="https://investorplace.com/stock-quotes/indo-stock-quote/">INDO</a>) shares close out our pre-market stock movers down over 10%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-april-22nd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

SBFM, BPTH and INDO among pre-market losers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Hepion Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/hepa-stock-quote/">HEPA</a>) stock is diving on Monday after the biopharmaceutical company announced plans to <a href="https://www.nasdaq.com/press-release/hepion-pharmaceuticals-initiates-wind-down-activities-in-phase-2b-ascend-nash-trial">wind down a clinical trial</a>.



A press release from the company notes that it is winding down it Phase 2b ASCEND-NASH study. The failure of the study comes as it couldn&rsquo;t reach the planned 336 patients. Instead, it only got to 151 patients.



On top of this, Hepion Pharmaceuticals is struggling with resources as the company is exploring strategic alternatives. This didn&rsquo;t leave it with enough room to keep the trial going while waiting for more patients to enroll.



Hepion Pharmaceuticals executive chairman John Brancaccio said the following about the news.




&ldquo;We are disappointed to announce the wind-down of our Phase 2 NASH trial, which we attribute entirely to resource constraints. Given the number of enrolled NASH patients to date and the low probability of generating relevant efficacy data to support a registrational trial with our current cash resources, we have opted to wind down the program and assure that patients are transitioned out of the trial in a safe and compliant manner.&rdquo;




<h2>HEPA Stock Movement Today</h2>



With this news comes a 40.5% drop for HEPA stock on Monday morning. Investors will note that the shares were already down 36.2% year-to-date when markets closed on Friday.



This also comes with around 39,000 shares traded. The company&rsquo;s daily average trading volume is still above that at 75,000 shares.



Investors will find even more of the most recent stock market stories ready to go below!



We are offering insight into the top stock market news for Monday! That includes everything happening with shares of Vaxxinity&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/vaxx-stock-quote/">VAXX</a>) stock, OLB Group&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/olb-stock-quote/">OLB</a>) stock and Moolec Science&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mlec-stock-quote/">MLEC</a>) stock today. You can find out more on these matters at the following links!



<h2>More Stock Market News for Monday</h2>



<ul><li><a href="https://investorplace.com/2024/04/why-is-vaxxinity-vaxx-stock-down-58-today/">Why Is Vaxxinity (VAXX) Stock Down 58% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-olb-group-olb-stock-up-27-today/">Why Is OLB Group (OLB) Stock Up 27% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-moolec-science-mlec-stock-up-121-today/">Why Is Moolec Science (MLEC) Stock Up 121% Today?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/why-is-hepion-pharmaceuticals-hepa-stock-down-41-today/">Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Nike (NYSE:<a href="https://investorplace.com/stock-quotes/nke-stock-quote/">NKE</a>) layoffs are in the news Monday after the athletic apparel company announced plans to <a href="https://www.kgw.com/article/money/business/nike-740-layoffs-world-headquarters-beaverton/283-3d676a3c-957d-4110-92bd-d5f7a9c793e9">cut jobs at its global headquarters</a>.



These Nike layoffs will result in 740 employees at the company&rsquo;s Beaverton, Oregon, headquarters losing their jobs. This comes after the company announced plans to reduce its workforce by 2% in February.



Nike is planning to handle these layoffs in two rounds. The first round will start immediately, and the second round will <a href="https://www.usatoday.com/story/money/business/2024/04/20/nike-layoffs-2024/73396096007/">start by June 28</a>. It&rsquo;s worth noting that Nike currently has about 11,000 employees at its headquarters and 83,000 total.



All of this is part of a restructuring effort that has 1,600 jobs being cut at Nike. The company estimates that these changes will save it $2 billion per year and that it will suffer a $400 million to $450 million charge connected to them.



<h2>Nike Layoffs Statement</h2>



Here&rsquo;s what the company had to say about the layoffs to KGW8:




&ldquo;Nike&rsquo;s always at our best when we&rsquo;re on the offense. The actions that we&rsquo;re taking put us in the position to right-size our organization to get after our biggest growth opportunities as interest in sport, health and wellness have never been stronger.&rdquo;




NKE stock is down slightly on Monday morning after announcing this newest round of layoffs.



Investors who are seeking out even more of the most recent stock market stories are in luck!



We have all of the hottest stock market news for Monday! Among that is what has shares of Tesla&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/tsla-stock-quote/">TSLA</a>), Hepion Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/hepa-stock-quote/">HEPA</a>) and Vaxxinity (NASDAQ:<a href="https://investorplace.com/stock-quotes/vaxx-stock-quote/">VAXX</a>) stock in the news today. You can read up on all of this news at the links below!



<h2>More Monday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/04/tsla-stock-alert-tesla-plunges-on-another-round-of-ev-price-cuts/">TSLA Stock Alert: Tesla Plunges on Another Round of EV Price Cuts</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-hepion-pharmaceuticals-hepa-stock-down-41-today/">Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-vaxxinity-vaxx-stock-down-58-today/">Why Is Vaxxinity (VAXX) Stock Down 58% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/nike-layoffs-2024-what-to-know-about-the-latest-nike-job-cuts/">Nike Layoffs 2024: What to Know About the Latest Nike Job Cuts</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Nike Layoffs 2024: What to Know About the Latest Nike Job Cuts

MRIN, WISA and SMFL among mid-day movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Hepion Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/hepa-stock-quote/">HEPA</a>) just reported results for the first quarter of 2024.<ul><li>Hepion Pharmaceuticals reported earnings per share of -56 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/hepa-stock-earnings-hepion-pharmaceuticals-for-q1-of-2024/">HEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

HEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q1 2024

An update from Hepion Pharmaceuticals (HEPA) is now available. Hepion Pharmaceuticals has entered into a merger agreement with Pharma Two B Ltd. an...

Hepion Pharmaceuticals' Strategic Merger and Corporate Restructuring

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Hepion Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/hepa-stock-quote/">HEPA</a>) just reported results for the second quarter of 2024.<ul><li>Hepion Pharmaceuticals reported earnings per share of -68 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/hepa-stock-earnings-hepion-pharmaceuticals-for-q2-of-2024/">HEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

HEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q2 2024

AGBA

AILE

AKRO

ARWR

ASCLF

BPTH

BPTS

BSGM

CAPT

CHRO

CSLR

DRMA

EDBL

ETNB

EZFL

GALT

GILD

GLMD

GRTX

HGAS

HUBC

INDO

INVO

IONS

MDGL

MDIA

MNDR

MRIN

NKGN

NVFY

PAAS

PALI

PROK

PRTG

RWOD

SBFM

SGMT

SMFL

SOAR

SPCB

TELO

TERN

TRSG

TSLA

VKTX

VZLA

WISA

YYGH

ZCMD

Press Releases

Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 'ALTITUDE-NASH' Liver Function Trial of Rencofilstat

Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease

Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit

Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes

Hepion Pharmaceuticals to Present at NASH-TAG 2024

Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds

Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell

Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' Trial

Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Hepion Pharmaceuticals

Hepion Pharmaceuticals (HEPA) Forecast

Hepion Pharmaceuticals (NASDAQ:HEPA) Stock, Quote.Headers.trade-ideas